These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. Jacobsen PL; Nomikos GG; Zhong W; Cutler AJ; Affinito J; Clayton A CNS Spectr; 2020 Feb; 25(1):50-63. PubMed ID: 31010445 [TBL] [Abstract][Full Text] [Related]
44. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Cantrell CR; Eaddy MT; Shah MB; Regan TS; Sokol MC Med Care; 2006 Apr; 44(4):300-3. PubMed ID: 16565629 [TBL] [Abstract][Full Text] [Related]
45. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy. Strawn JR; Mills JA; Croarkin PE J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350 [No Abstract] [Full Text] [Related]
46. Pediatrician and family physician prescription of selective serotonin reuptake inhibitors. Rushton JL; Clark SJ; Freed GL Pediatrics; 2000 Jun; 105(6):E82. PubMed ID: 10835095 [TBL] [Abstract][Full Text] [Related]
47. Does the use of SSRIs reduce medical care utilization and expenditures? Chung S J Ment Health Policy Econ; 2005 Sep; 8(3):119-29. PubMed ID: 16278500 [TBL] [Abstract][Full Text] [Related]
48. Association of Selective Serotonin Reuptake Inhibitor Use With Abnormal Physical Movement Patterns as Detected Using a Piezoelectric Accelerometer and Deep Learning in a Nationally Representative Sample of Noninstitutionalized Persons in the US. Heinz MV; Price GD; Ruan F; Klein RJ; Nemesure M; Lopez A; Jacobson NC JAMA Netw Open; 2022 Apr; 5(4):e225403. PubMed ID: 35389502 [TBL] [Abstract][Full Text] [Related]
49. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Waldinger MD; Hengeveld MW; Zwinderman AH; Olivier B J Clin Psychopharmacol; 1998 Aug; 18(4):274-81. PubMed ID: 9690692 [TBL] [Abstract][Full Text] [Related]
50. Long-term costs of treatment for depression: impact of drug selection and guideline adherence. Crown WH; Treglia M; Meneades L; White A Value Health; 2001; 4(4):295-307. PubMed ID: 11705297 [TBL] [Abstract][Full Text] [Related]
51. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Stein MB; Cantrell CR; Sokol MC; Eaddy MT; Shah MB Psychiatr Serv; 2006 May; 57(5):673-80. PubMed ID: 16675762 [TBL] [Abstract][Full Text] [Related]
53. Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events. Czaja AS; Valuck RJ; Anderson HD Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):607-14. PubMed ID: 23456956 [TBL] [Abstract][Full Text] [Related]
54. Venlafaxine extended-release: a review of its use in the management of major depression. Wellington K; Perry CM CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036 [TBL] [Abstract][Full Text] [Related]
55. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835 [TBL] [Abstract][Full Text] [Related]
56. Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data. Berndt ER; Russell JM; Miceli R; Colucci SV; Xu Y; Grudzinski AN Value Health; 2000; 3(3):208-21. PubMed ID: 16464185 [TBL] [Abstract][Full Text] [Related]
58. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. Foster RH; Goa KL CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224 [TBL] [Abstract][Full Text] [Related]
59. Efficacy of controlled-release paroxetine in the treatment of late-life depression. Rapaport MH; Schneider LS; Dunner DL; Davies JT; Pitts CD J Clin Psychiatry; 2003 Sep; 64(9):1065-74. PubMed ID: 14628982 [TBL] [Abstract][Full Text] [Related]
60. Association of selective serotonin re-uptake inhibitor (SSRI) treatment with acute substance misuse outcomes. Virtanen S; Lagerberg T; Khemiri L; Suvisaari J; Larsson H; Lichtenstein P; Chang Z; Latvala A Addiction; 2022 Jan; 117(1):234-242. PubMed ID: 34185347 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]